Editors’ Picks, November 2024: Cervical Cancer in Native Americans, Nanovaccines, and More

The cover of Cancer Prevention Research was adopted from a figure in the study that showed the abundance of bacteria in the vaginal microbiome. As we head into the holiday season, Cancer Research Catalyst has tantalizing teasers in the form of science stocking stuffers straight from our November edition of Editors’ Picks. This month, the… Continue reading Editors’ Picks, November 2024: Cervical Cancer in Native Americans, Nanovaccines, and More

Getting the right combination to break the epigenetic code

Abstract Rapid advances in the field of epigenetics have facilitated the development of novel therapeutics targeting epigenetic mechanisms that are hijacked by cancer cells to support tumour growth and progression. Several epigenetic agents have been approved by the FDA for the treatment of cancer; however, the efficacy of these drugs is dependent on the underlying… Continue reading Getting the right combination to break the epigenetic code

The most extensive epigenetic database of malignant blood cells created

Researchers published a dataset covering thousands of methylated sites from hundreds of cancer-derived cultured cells, covering many leukemias, lymphomas and myelomas, from humans and mice. With this data, any researcher can access the epigenetic signature of these tumors for research and clinical purposes. Researchers published a dataset covering thousands of methylated sites from hundreds of… Continue reading The most extensive epigenetic database of malignant blood cells created

YAP enhances mitochondrial OXPHOS in tumor-infiltrating Treg through upregulating Lars2 on stiff matrix

Background Tumor-infiltrating regulatory T cells (TI-Tregs) are well-adapted to thrive in the challenging tumor microenvironment (TME) by undergoing metabolic reprogramming, notably shifting from glycolysis to mitochondrial oxidative phosphorylation (OXPHOS) for energy production. The extracellular matrix is an important component of the TME, contributing to the regulation of both tumor and immune cell metabolism patterns by… Continue reading YAP enhances mitochondrial OXPHOS in tumor-infiltrating Treg through upregulating Lars2 on stiff matrix

‘Moonlighting’ enzymes can lead to new cancer therapies

Researchers reveal that metabolic enzymes known for their roles in energy production and nucleotide synthesis are taking on unexpected ‘second jobs’ within the nucleus, orchestrating critical functions like cell division and DNA repair. The discovery not only challenges longstanding biological paradigms in cellular biology but also opens new avenues for cancer therapies, particularly against aggressive… Continue reading ‘Moonlighting’ enzymes can lead to new cancer therapies

Selective Vulnerability of GABAergic Inhibitory Interneurons to Bilirubin Neurotoxicity in the Neonatal Brain

Hyperbilirubinemia (HB) is a key risk factor for hearing loss in neonates, particularly premature infants. Here, we report that bilirubin (BIL)-dependent cell death in the auditory brainstem of neonatal mice of both sexes is significantly attenuated by ZD7288, a blocker for hyperpolarization-activated cyclic nucleotide-gated (HCN) channel-mediated current (Ih), or by genetic deletion of HCN1. GABAergic… Continue reading Selective Vulnerability of GABAergic Inhibitory Interneurons to Bilirubin Neurotoxicity in the Neonatal Brain

Why Elephants Don’t Get Cancer but Ferrets Do: Cancer Prevalence Across Vertebrate Animals

In 1977, Sir Richard Peto, FRS, FAACR, postulated that larger animals with longer lifespans should develop cancer more readily than their smaller, shorter-lived companions. Since cancer is driven largely by errors in DNA replication, animals with more cells and more time to accumulate mutations should also develop more cancer, he argued.  He observed, however, that this does… Continue reading Why Elephants Don’t Get Cancer but Ferrets Do: Cancer Prevalence Across Vertebrate Animals